Opitor-0

Opitor-0 is a OPA1 GTPase inhibitor with an IC50 of 3.0 μM. Opitor-0 disrupts mitochondrial cristae structure and respiratory efficiency, induces mitochondrial fragmentation, enhances cBID-mediated cytochrome c release, and restores the sensitivity of triple-negative breast cancer (TNBC) cells to ABT-737 (HY-50907). Opitor-0 selectively reduces the migration and proliferation capacities of metastatic breast cancer cells, and induces cell death and apoptosis. Opitor-0 can be used in studies related to metastatic breast cancer and triple-negative breast cancer .


Cat. No.: EX-A16629	Purity: >98%

	Chemical structure of Opitor-0

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
50mg	750	In-stock
100mg	1250	In-stock
250mg	1950	In-stock
500mg	2950	In-stock
1g	4120	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Purity	>98%
Formula	C30H25N5O2S
Mol Weight	519.617
Color	Off-white to yellow
State	Solid
Solubility	DMSO : 35 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1].Diokmetzidou A, et al. Metastatic breast cancer cells are selectively dependent on the mitochondrial cristae-shaping protein OPA1. Cell death & disease. 2025 Jul 21;16(1):539. [2].Pellattiero A, et al. Small molecule OPA1 inhibitors amplify cytochrome c release and reverse cancer cells resistance to Bcl-2 inhibitors. Sci Adv. 2025 Jul 4;11(27):eadx4562.
CoA	CoA of Opitor-0

Smiles:	CC1=NN(C2=CC=CC=C2)C3=C1C=C(C(NC(C(N(N4CC5=CC=CC=C5)C6=CC=CC=C6)=O)=C4C)=O)S3


		Search